GeoVax Labs, Inc. — 2013 Form 10-K
Reporting period: Fiscal year ended December 31, 2013. The filing also presents unaudited quarterly results, including fourth-quarter 2013. GeoVax is a development-stage biotechnology company developing preventive and therapeutic HIV vaccines; it had no approved products or product-sale revenue.
Financial performance and liquidity
| Metric | 2013 | 2012 |
|---|---|---|
| Grant revenue | $2.418 million | $2.657 million |
| Research and development expense | $2.915 million | $3.044 million |
| General and administrative expense | $1.792 million | $1.753 million |
| Net loss | $2.285 million | $2.135 million |
| Net loss per share | $0.11 | $0.12 |
| Net cash used in operating activities | $1.695 million | $2.441 million |
Grant revenue is NIH funding recognized as related costs are incurred, not sales revenue. Operating expenses exceeded grant revenue, producing a $2.289 million operating loss in 2013. No product gross margin is applicable. Fourth-quarter 2013 grant revenue was $174,738 and net loss was $871,714; the filing does not provide a clear explanation for the quarter’s higher loss relative to the preceding quarter.
At year-end, cash and cash equivalents were $2.514 million, working capital was $2.386 million, total assets were $2.840 million, and total current liabilities were $312,349. The company reported no committed lines of credit or long-term debt. It said cash and remaining NIH grant funding were expected to support planned operations into the first quarter of 2015, while anticipating a need for additional financing. Accumulated deficit was $27.1 million.
Financing activities provided $3.259 million in 2013, including warrant exercises and approximately $1.6 million in net proceeds from a Series B preferred-stock offering. The company reported 23.765 million common shares outstanding at year-end and 24.968 million as of March 10, 2014. Preferred conversions and warrants create potential dilution.
Changes versus the prior year
- Grant revenue declined about 9% year over year, reflecting lower grant-supported spending.
- Net loss increased about 7%, despite lower R&D expense, as general and administrative expense rose modestly.
- Operating cash use improved by approximately $747,000. Year-end cash increased by approximately $1.478 million, supported by equity financing.
- In December, the company issued Series B preferred stock and reduced the conversion price of remaining Series A preferred stock and the exercise price of certain warrants to $0.35.
Programs, outlook, and risks
- Therapeutic vaccine: GeoVax reported early Phase 1 results for GOVX-B11 in nine HIV-positive participants: enhanced CD8+ T-cell responses in 8 of 9, CD4+ responses in 5 of 9, and boosted antibody responses in 4 of 9. The company reported good safety during the study; exploratory observations on viral control are preliminary, not evidence of efficacy.
- Preventive vaccine: Completed Phase 2a HVTN 205 results showed Env-binding antibody responses at peak in 93.2% of the DNA/MVA group and 98.4% of the MVA-only group. The company selected unadjuvanted GOVX-B11 for further preventive development after preliminary comparison did not show significant preventive benefit from the GM-CSF adjuvant in GOVX-B21.
- GeoVax was discussing next preventive-trial designs with the HVTN and NIH, including a possible protein boost. Management expected a next preventive trial to start in 2015 and anticipated NIH funding, but said study details and support were not assured. A follow-on therapeutic study of GOVX-B21 was being planned, with NIH funding sought.
- Approximately $822,000 in approved NIH grant funds remained available at year-end. Management expected future losses and rising development costs and planned to seek grants and additional equity, debt, or convertible financing. Financing may not be available on acceptable terms or at all.
- Key risks include clinical or regulatory failure, dependence on NIH/HVTN support and third-party manufacturers, need for substantial additional capital, dilution, competition, and intellectual-property and commercialization risks. The company had no material legal proceedings. The independent auditor issued an unqualified opinion; management concluded internal controls were effective as of year-end.
Investor verification points
- Review the audited financial statements and grant disclosures to confirm remaining NIH funds, grant recognition, and the company’s stated cash runway.
- Track actual financing proceeds, cash burn, and potential dilution from preferred-stock conversions, options, and warrants.
- Verify subsequent NIH/HVTN decisions, trial design, funding, and timing; distinguish preliminary immune-response findings from demonstrated clinical benefit.
- Assess the consequences of the GOVX-B21 preventive-program decision and the rationale for selecting GOVX-B11 for further study.
- Review the terms and conversion status of Series A and Series B preferred stock and the anti-dilution provisions affecting warrants.